Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome caused by mutations in the NF1 gene. The NF1-encoded protein (neurofibromin) is an inhibitor of the oncoprotein RAS and controls cell growth and survival. Individuals with NF1 are prone to developing low-grade tumors of the optic nerves, chiasm, tracts, and radiations, termed optic pathway gliomas (OPGs), which can cause vision loss. A paucity of surgical tumor specimens and of patient-derived xenografts for investigative studies has limited our understanding of human NF1-associated OPG (NF1-OPG). However, mice genetically engineered to harbor Nf1 gene mutations develop optic gliomas that share many features of their human counterparts. These genetically engineered mouse (GEM) strains have provided important insights into the cellular and molecular determinants that underlie mouse Nf1 optic glioma development, maintenance, and associated vision loss, with relevance by extension to human NF1-OPG disease. Herein, we review our current understanding of NF1-OPG pathobiology and describe the mechanisms responsible for tumor initiation, growth, and associated vision loss in Nf1 GEM models. We also discuss how Nf1 GEM and other preclinical models can be deployed to identify and evaluate molecularly targeted therapies for OPG, particularly as they pertain to future strategies aimed at preventing or improving tumor-associated vision loss in children with NF1.
| I N TR ODU C TI ON
Tumors of the visual system occur in a number of inherited disorders, including retinoblastoma, which is caused by germline mutations in the RB1 gene (Vogel, 1979) , retinal astrocytic hamartoma in tuberous sclerosis (Rowley, O'Callaghan, & Osborne, 2001) , retinal hemangioblastoma in von Hippel-Lindau disease (Lonser et al., 2003) , optic nerve (ON) sheath meningioma in neurofibromatosis type 2 (Bosch, Wichmann, Boltshauser, & Landau, 2006) , and optic pathway glioma (OPG) in neurofibromatosis type 1 (NF1) (Listernick, Ferner, Liu, & Gutmann, 2007) . Of these disorders, NF1 is the most common, affecting 1 in 3,000 individuals worldwide (Crowe, 1956; Evans et al., 2010; Friedman, 1999; Huson, Compston, Clark, & Harper, 1989) .
NF1 is an autosomal dominant syndrome caused by loss-offunction mutations in the NF1 tumor suppressor gene Viskochil et al., 1990; Wallace et al., 1990) , which encodes the protein neurofibromin. Comprising more than 2,800 amino acids (220 kDa), neurofibromin contains a small domain (280-300 amino acids) that is structurally and functionally similar to a family of proteins that are negative RAS regulators (Basu et al., 1992; Bollag & McCormick, 1991; Xu, Lin, et al., 1990; Xu, O'Connell, et al., 1990) . Consistent with increased RAS activation being associated with numerous human cancers (Fernandez-Medarde, & Santos, 2011) , individuals with NF1 are
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predisposed to a range of tumors affecting the central and peripheral nervous systems, including OPGs, which are a source of significant morbidity in this population (Listernick et al., 2007) .
Nearly all NF1-associated OPGs (NF1-OPGs) are benign pilocytic astrocytomas (World Health Organization grade I astrocytomas), and they may arise anywhere along the optic pathway, including the optic nerves, optic chiasm, optic tracts, and optic radiations (Guillamo et al., 2003; Liu et al., 2004) (Figure 1a -c). In individuals with NF1, the majority (75-85%) of OPGs are located within the ON and chiasm (pre-chiasmal or anterior optic pathway), with a smaller proportion of tumors located in the optic tracts and radiations (post-chiasmal or posterior optic pathway). NF1-OPGs occur most frequently in young children (median age at diagnosis 5 4.5 years) (Listernick, Charrow, Greenwald, & Esterly, 1989; Listernick, Charrow, Greenwald, & Mets, 1994; Prada et al., 2015) , with rare cases described in older adolescents (Chong et al., 2013; Listernick et al., 2004) . Hence, OPG is a manifestation of NF1 that predominates in young children who are often preverbal with comorbid attention deficits, further complicating diagnosis and accurate visual assessment in an at-risk population (Listernick et al., 2007) . NF1-OPGs demonstrate significant clinical heterogeneity in their location, age at initial detection, and tumor-associated vision loss (Listernick et al., 1994) . Risk factors for vision loss from NF1-OPG are: age less than 2 years (Fisher et al., 2012) , female sex (Diggs-Andrews, , and tumor involvement of the post-chiasmal optic pathway (Balcer et al., 2001; Fisher et al., 2012) . Treatment is usually reserved for patients with progressive symptoms (e.g., vision loss) and frequently involves chemotherapy. While most symptomatic children are treated with carboplatin/vincristine therapy (Mahoney et al., 2000; Packer et al., 1993; Packer et al., 1997) , molecularly targeted therapies have recently emerged. Chemotherapy often successfully attenuates tumor growth (60-70% response rates), however, few patients have improved visual acuity following treatment (Dalla Via et al., 2007; Dodgshun, Elder, Hansford, & Sullivan, 2015; Fisher et al., 2012; Listernick et al., 2007; Shofty et al., 2011) .
Most patients who receive chemotherapy do not have a prior tissue diagnosis (tumor biopsy), and few patients undergo surgical resection of their tumors. The lack of human tumor specimens for study has hindered efforts to understand the molecular and cellular determinants of human NF1-OPG and to discover new therapeutic leads. To this end, much of our understanding of NF1-OPG draws from studies of mice engineered to harbor mutations in the Nf1 gene (Nf1 GEM models) (Gutmann, Parada, Silva, & Ratner, 2012) . In this review, we describe insights from Nf1 GEM models NF1-OPG pathobiology, including mechanisms underlying vision loss. We further discuss promising leads in the development of molecularly targeted and neuroprotective therapies relevant to preventing or limiting vision loss.
| TU M OR I GEN E S IS I N N F 1 RE QU I RE S BI A L LE LI C I NA CTI V A TI ON OF TH E N F1 GE NE
Individuals without NF1 are born with two functional copies (alleles) of the NF1 gene. In contrast, individuals with NF1 are born with one functional NF1 allele and another allele harboring a loss-of-function NF1 gene mutation (referred to as the germline mutation). For tumorigenesis to occur in individuals with NF1, a vulnerable cell type (i.e., glioma cell of origin) must undergo somatic inactivation of the remaining functional NF1 allele, resulting in a cell in which both NF1 alleles are nonfunctional (Brems et al., 2009; Laycock-van Spyk, Thomas, Cooper, & Upadhyaya, 2011; Maertens et al., 2006) . This "two-hit" model of tumorigenesis was first proposed for retinoblastoma (Knudson, 1971) and applies to many other inherited cancer predisposition syndromes.
Commensurate with this "two-hit" model, human NF1-associated pilocytic astrocytomas demonstrate simultaneous presence of a germline NF1 gene mutation and somatic inactivation of the inherited functional NF1 allele. Somatic NF1 gene inactivation in tumors can result from loss of heterozygosity, genetic mutation, or epigenetic modification (e.g., methylation) of the NF1 locus (Gutmann et al., 2003 (Gutmann et al., , 2013 Kluwe et al., 2001 ), all leading to undetectable levels of neurofibromin (the protein encoded by NF1) in tumor cells (Gutmann, Donahoe, Brown, James, & Perry, 2000) . Loss of neurofibromin function in these cells predisposes them to inappropriately regulated cell proliferation or survival, thereby facilitating tumor formation.
The first genetically engineered mouse (GEM) models of NF1 harbored a germline inactivating mutation resulting in a non-functional (null or knockout) Nf1 allele (Brannan et al., 1994; Jacks et al., 1994) There is a growing consensus that for many pediatric and adult brain tumors, the cells of origin-that is, those cells that initiate a tumor-are neural stem/progenitor cells (NPCs) (Hemmati et al., 2003; Schuller et al., 2008; Yang et al., 2008) . To identify the putative cell(s) of origin for NF1-OPG, studies in mice have iteratively applied different Cre driver lines using the genetic strategy described above to target somatic Nf1 loss to various NPC types. In these experiments, the endogenous promoters (gene expression regulatory sequences), or fragments thereof, of the genes Gfap, Blbp, and Prom1 (CD133) drove
Cre recombinase in NPCs expressing these genes, thereby producing Nf1 gene inactivation (Bajenaru et al., 2003; Hegedus et al., 2007; Solga et al., 2017) . In each of these three Nf1 GEM models, mice Finally, studies using the Nf1 flox/null , Prom1-cre mouse strain, in which Cre recombinase activity is induced with tamoxifen exposure (L. Zhu et al., 2009) , assessed the consequence of somatic Nf1 inactivation at different developmental time points. In these studies, Nf1 loss in Prom1-expressing cells was required prior to postnatal day 1 for optic gliomas to form, arguing that there is a developmental window during which somatic Nf1 gene inactivation must occur in order to facilitate gliomagenesis . Taken together, these findings argue that mouse Nf1 optic glioma formation is heavily influenced by the cell of origin and by the requirement for somatic Nf1 gene inactivation to occur in specific cell types during brain development, consistent with the clinical observation that NF1-OPGs are largely a tumor of young children.
| Deregulated RAS pathway activity contributes to NF1-OPG pathobiology
Individuals with NF1 harbor germline mutations in the NF1 gene located on chromosome 17q11.2. The NF1 gene encodes neurofibromin, which functions primarily as a GTPase activating protein (GAP) for the oncoprotein RAS. Neurofibromin contains a 300-amino acid residue GAP-related domain, which inhibits RAS activity by accelerating the conversion of active GTP-bound RAS to its inactive GDP-bound form (Ballester et al., 1990; Ohba et al., 2000; Xu, Lin, et al., 1990) .
RAS is a small GTPase important for promoting cell growth and survival in numerous cell types, including the developing and mature mammalian brain, and gain-of-function mutations in the RAS proto-oncogene are frequently found in human cancers (Fernandez-Medarde & Santos, 2011; Simanshu, Nissley, & McCormick, 2017) . In humans, NF1-associated tumor cells with biallelic NF1 gene inactivation (i.e., lacking neurofibromin protein) exhibit elevated RAS activity (Basu et al., 1992; Bollag et al., 1996; DeClue, Cohen, & Lowy, 1991) , and studies in Nf1
GEM models similarly support a critical role for aberrant RAS pathway activation in tumor pathogenesis.
As a critical growth regulator, RAS may transmit its signal through at least three downstream effector pathways that each contribute to
Nf1 optic glioma pathogenesis in mice. These pathways include: (1) the RAS-MEK-ERK pathway (Donovan, See, Bonifas, Stokoe, & Shannon, 2002; Lau et al., 2000; See, Tan, Mukherjee, Nicolaides, & Pieper, 2012) , (2) the PI3K-AKT-mTOR pathway (Dasgupta, Yi, Chen, Weber, & Gutmann, 2005; Johannessen et al., 2005; Lau et al., 2000) , and (3) the adenylyl cyclase-mediated cyclic AMP (cAMP) signaling pathway (Anastasaki & Gutmann, 2014; Warrington et al., 2010) .
In tumor cells lacking neurofibromin (termed NF1-deficient), the first two pathways (i.e., the RAS-MEK-ERK and PI3K-AKT-mTOR pathways) are upregulated ( Figure 2a ). These two pathways can converge to activate mTOR (Kaul, Toonen, Cimino, Gianino, & Gutmann, 2015) , a serine/threonine kinase that positively regulates cell growth, survival, and proliferation (Laplante & Sabatini, 2012) . In addition, findings reveal mTOR-independent growth regulatory functions of the RAS-MEK-ERK pathway . In the third RAS effector pathway, elevated RAS activity leads to reduced cAMP production through signaling intermediates that likely converge on the enzyme adenylyl cyclase, which ultimately generates cAMP (Figure 2a ). Pharmacologic modulation of any of the three RAS effector pathways slows tumor growth in mice with Nf1 optic gliomas (Hegedus et al., 2008; Kaul et al., 2015) .
Inhibition of (1) the RAS-MEK-ERK pathway using the MEK inhibitor PD0325901, (2) the PI3K-AKT-mTOR pathway, using the PI3K inhibitor NPV-BKM120, or (3) mTOR using rapamycin decreases tumor cell proliferation and tumor volumes in mice (Hegedus et al., 2008; Kaul et al., 2015) . Also, increasing intracellular cAMP levels with the phosphodiesterase-4 inhibitor rolipram reduces tumor proliferation and size (Warrington et al., 2010) . Unfortunately, all of these clinical-grade inhibitors attenuate mouse Nf1 optic glioma growth only during the period of treatment, and tumors increase their proliferation to pretreatment levels following the cessation of therapy (Hegedus et al., 2008) .
The lack of a durable response may be problematic for treating these tumors in children, possibly necessitating prolonged treatment periods.
In addition to its role in promoting the survival and proliferation in NF1-deficient tumor cells, aberrant RAS pathway activity also contributes to axonal dysfunction and death of NF1-mutant RGCs, with relevance to visual dysfunction (Figure 2b ). RGCs are the visual pathway neurons that convey light information from the retina to the brain.
RGC bodies reside in the innermost layer of the retina (termed the ganglion cell layer), and their axons course through the RNFL before forming the ONs (Figure 3a,b) . In individuals with NF1, RGCs are heterozygous for a germline NF1 gene mutation (termed NF1-mutant). In these NF1-mutant RGCs, impaired neurofibromin function lowers cAMP levels and decreases cell survival (Brown, Gianino, & Gutmann, 2010) , an effect of cAMP opposite to that observed in Nf1-deficient tumor cells. Studies in other neuron types harboring NF1 gene mutations (e.g., hippocampal neurons, human-induced pluripotent cellderived neurons) implicate neurofibromin/RAS-mediated activation of the atypical protein kinase C zeta (PKCf) as the likely mechanism for this RGC-specific reduction in cAMP (Anastasaki & Gutmann, 2014) .
Increased PKCf activity leads to inhibition of G protein-coupled receptor stimulation of G protein-mediated adenylyl cyclase activity (Anastasaki & Gutmann, 2014) . Correspondingly, pharmacologic inhibition of RAS activity (lovastatin) or elevation of cAMP levels (rolipram) attenuates RGC apoptosis in Nf1 optic glioma-bearing mice (Brown et al., 2010; . Recent proof-of-principle preclinical studies showed that RAS inhibition (and cAMP elevation) during a period after RGC death and RNFL thinning begins, but before more than 30% of RGCs are lost, protects against continued RGC loss and RNFL thinning for up to 2 months following the cessation of treatment and tumor cell proliferation (Daginakatte, Gianino, Zhao, Parsadanian, & Gutmann, 2008; Simmons et al., 2011) . Microglia promote glioma formation and growth through the elaboration of growth factors and chemokines, including chemokine ligand 5 (CCL5) (Solga et al., 2015) and stromal cell-derived factor 1 (CXCL12) (Warrington et al., 2007) (Figure 3d ). Inhibition of these chemokine/receptor axes with pharmacological inhibitors (blocking the association between CXCL12 and its cognate receptor CXR4) or neutralizing antibodies reduces glioma growth. These preclinical proof-ofconcept studies collectively reveal an obligate role for microglia in glioma pathogenesis and suggest therapeutic targets for future stromaldirected treatment approaches.
| Nf1 optic glioma vision loss is sexually dimorphic
In both humans and mice, vision loss from optic gliomas is caused by loss of RGCs. In mice harboring Nf1 optic gliomas, there is a stereotyped pattern of visual system pathology, beginning with RGC axonal damage, followed by increased RGC apoptosis and RNFL thinning, and culminating in decreased visual acuity (Hegedus et al., 2009; Kim, Ju, Hegedus, Gutmann, & Ellisman, 2010; Toonen, Ma, et al., 2017) .
Studies in mice have revealed two etiologies-one cell autonomous
and one cell nonautonomous-that underlie optic glioma-associated death of Nf1-mutant RGCs. First, Nf1-mutant RGCs, by virtue of their impaired neurofibromin function, have baseline reduced levels of intracellular cAMP, which lowers the threshold for RGC death in the setting of neuroinflammatory or neurotoxic stimuli (Brown et al., 2010) (Figure   3c ). Second, specifically in female mice, gonadal estradiol acts through the estrogen receptor b (ERb) to stimulate Nf1-mutant microglia, thereby causing Nf1-mutant RGC death, thinning of the RNFL (which comprises RGC axons), and decreased visual acuity (Diggs-Andrews, Brown, Gianino, . Sexually dimorphic retinal pathology in Nf1 optic glioma mice is independent of tumor size and can be corrected by pharmacologic inhibition of microglial activation, ERb blockade, or chemical or surgical ovariectomy . In this cell nonautonomous mechanism, microglia are hypothesized to secrete neurotoxic cytokines (e.g., IL-1b) that either directly or indirectly damage RGC axons (Figure 3d ), perhaps through disruption of normal axo-glial contacts as seen in other forms of axonal injury (Howell et al., 2010) . Together, reduced cAMP levels and microglial production of neurotoxic cytokines likely synergize to culminate in RGC death and vision loss in mice harboring Nf1 optic gliomas. While investigations have revealed some of the mechanisms underlying sexually dimorphic vision loss in mice, the etiology of the increased risk for vision loss in girls with NF1-OPG remains to be identified (Diggs-Andrews, Brown, Gianino, D'Agostino McGowan, et al., 2014; Fisher et al., 2014) .
| The germline Nf1 gene mutation differentially impacts murine optic glioma pathogenesis
Converging evidence from population-based clinical studies and preclinical studies using human induced pluripotent stem cells (iPSCs) and genetically engineered mice has revealed intriguing genotypephenotype correlations in NF1. For example, children with NF1 who harbor mutations in the 5 0 -end of the NF1 gene coding sequence are more likely to develop OPGs than patients with mutations elsewhere in the coding sequence (Anastasaki, Le, Kesterson, & Gutmann, 2017; Sharif et al., 2011) . In addition, human iPSCs derived from individuals with NF1 (i.e., cells heterozygous for a patient-specific germline NF1 gene mutation) have variable neurofibromin protein levels and function (Anastasaki, Woo, Messiaen, & Gutmann, 2015) . Finally, isogenic mouse strains engineered to harbor distinct patient-specific Nf1 gene mutations exhibit markedly different tumor phenotypes. Specifically, mice with the Gly848Arg patient mutation do not form optic gliomas, whereas those harboring an Arg681X mutation develop optic gliomas of greater volumes and proliferative indices than those arising in mice harboring the artificial knockout allele (Toonen et al., 2016) . Together with other emerging genotype-phenotype correlations involving neurofibromas (Koczkowska et al., 2018; Pinna et al., 2015; Upadhyaya et al., 2007) and autism spectrum symptomatology (Morris & Gutmann, 2018) , these findings argue against the notion that all NF1 gene mutations are functionally equivalent (Anastasaki et al., 2015) , and support the idea that the germline NF1 gene mutation may in part determine disease penetrance and clinical heterogeneity. Studies are currently underway to identify the cell types that are differentially impacted by the germline NF1 gene mutation (i.e., microglia, RGCs) and to determine the mechanisms that underlie these effects.
| TH ER A P EU TI C I NS I G HTS

| Molecularly targeted and ecological therapies
Traditional cancer therapeutic strategies typically target cancer cells either through surgical removal or by inducing cell death using cytotoxic chemotherapy and/or radiation therapy. In NF1-OPG, treatment options have largely been limited to chemotherapy due to the diffusely infiltrative nature of the tumors, which precludes surgical resection (Alvord & Lofton, 1988) , and the heightened risk of radiation-induced secondary malignancy in this patient population (Evans, Birch, Ramsden, Sharif, & Baser, 2006; Sharif et al., 2006) . While frequently attenuating tumor growth, chemotherapies used to treat NF1-OPG are less clearly effective at preventing or reversing tumor-associated vision loss (Moreno, Bautista, Ashley, Duncan, & Zacharoulis, 2010) . Furthermore, their use is complicated by both short-and long-term side effects, ranging from fatigue and nausea to bone marrow suppression, hypersensitivity reactions, and permanent cognitive impairment (Packer et al., 1993; Verstappen, Heimans, Hoekman, & Postma, 2003) . More recently, molecularly targeted therapies, including inhibitors of the RAS effectors MEK and mTOR, have been used to treat patients with NF1-OPG in early-phase clinical trials (Banerjee et al., 2017; Yalon et al., 2013) . However, results from these studies have been mixed, underscoring the need for alternative therapeutic strategies, including those that aim to prevent or reduce vision loss from NF1-OPG.
With a growing appreciation for the key role of the low-grade glioma ecosystem in disease pathogenesis, new therapies that target emerged. In the case of NF1-OPGs, these "ecological therapies" (Hoelzinger, Demuth, & Berens, 2007; Pienta, McGregor, Axelrod, & Axelrod, 2008) , might target microglia/macrophages (Figure 3d ). Attenuating microglia recruitment and/or priming has been proposed for other tumor types, including glioblastoma and metastatic brain cancer (Andreou et al., 2017; Frazier et al., 2003; Hoelzinger et al., 2007) to create a supportive microenvironment may yield additional therapeutic targets. As one example, neuronal signaling to microglia (e.g., through the chemokine fractalkine, which binds the CX3CR1 receptor on microglia) is implicated in the modulation of microglia behavior in other neurodegenerative diseases (Paolicelli, Bisht, & Tremblay, 2014) .
Whether NF1-mutant RGCs similarly signal to NF1-mutant microglia in the context of NF1-OPG has yet to be determined. If relevant, such a signaling relationship would suggest additional targetable pathways for therapeutic exploration (Figure 3d ).
Finally, based on pioneering studies by Michelle Monje and colleagues, it is possible that neuronal activity influences tumor cell behavior through the elaboration of growth factors. Proof-of-principle experiments using a high-grade glioma mouse xenograft model showed that cortical neurons secrete neuroligin-3 (NLGN3) in an activitydependent manner to increase glioma cell proliferation and tumor growth (Venkatesh et al., 2015) . In NF1-OPG, the close anatomical proximity of NF1-deficient tumor cells to NF1-mutant RGC axons suggests the possibility that analogous neuron-to-tumor cell signaling relationships exist in optic gliomas (Figure 3d ). Further studies may determine whether RGC-to-tumor cell paracrine interactions are operative, which might additionally influence NF1-OPG pathogenesis.
| Future strategies for visual recovery in NF1-OPG
The currently available chemotherapeutic agents (e.g., carboplatin/vincristine), targeted RAS pathway inhibitors, and potential ecological therapies described above represent strategies for attenuating tumor growth. However, a limitation of these therapeutic strategies is that few are specifically designed to prevent continued vision loss in NF1-OPG. Potential future treatment approaches may promote RGC survival through elevation of cAMP levels (Brown et al., 2010) and/or through reduction of axonal damage from tumor-associated microglia.
Specifically, the latter approach might interfere with ERb-mediated microglia reprograming or disrupt the paracrine signaling pathways that culminate in axonal damage and RGC apoptosis (Hambardzumyan, Gutmann, & Kettenmann, 2016; McCarty, 2006 (Caprioli, Munemasa, Kwong, & Piri, 2009; Ishikawa et al., 2005; Mo et al., 2002) and glaucoma (Wilson & Di Polo, 2012) . Additionally, several groups are exploring the possibilities of reprograming M€ uller glia into RGCs to improve retinal function or of transplanting autologous human iPSC-derived RGCs into the retina (Jorstad et al., 2017; Sanges et al., 2016; Venugopalan et al., 2016) .
| CON CL U S I ONS
Herein, we describe the current state of understanding of the pathobiology of NF1-OPG and review insights from Nf1 GEM models relevant to the molecular and cellular determinants that underlie tumor formation, progression, and associated vision loss. The inherent limitations of mouse models underscore the need for additional small-animal models and other experimental platforms that capture the spectrum of clinical heterogeneity that characterizes these tumors in children with NF1.
First, future mouse modeling experiments should aim to include tumors that arise in the optic tracts and radiations, which represent the more clinically aggressive subtype in children with NF1. In addition, studies should incorporate mice harboring different germline Nf1 gene mutations, as seen in patients with NF1, as well as tumors harboring less common secondary genomic alterations (e.g., PTEN mutation, KIAA1549:BRAF duplication, fibroblast growth factor receptor-1 mutation) (Forshew et al., 2009; Jacques et al., 2010; Jones et al., 2008; Pfister et al., 2008; Zuckermann et al., 2015) .
Second, next-generation mouse preclinical trials should consider incorporating clinical endpoints used in human clinical trials, such as MRI and visual assessments. With the advent of high-resolution small-animal MRI (enabling measurement of tumor size) and ocular coherence tomography (enabling evaluation of RNFL thickness) (Avery et al., 2015; Gu, Glaug, Cnaan, Packer, & Avery, 2014) , future preclinical trials that include drug levels and clinically relevant outcomes could be designed.
Finally, complementary preclinical models should be considered.
Mice rely less on vision for survival, and their visual systems may not accurately represent the human condition. In this regard, there are ongoing efforts to develop genetically engineered models of NF1 in pigs (Meyerholz et al., 2017) . The visual system and brains of pigs more closely approximate those of humans and have already been used to model glaucoma (Ruiz-Ederra et al., 2005) . Swine may represent a more tractable large-animal model of NF1-OPG because of the greater anatomical similarity of the porcine retina to the human retina (compared to other large nonprimate mammals) (Prince, 1960) and their greater availability for study relative to primates.
There has been encouraging progress in our understanding of the pathophysiology of NF1-OPG since the discovery of the NF1 gene in 1990. With further study, it is possible that the future care of this unique population of individuals will include presymptomatic risk assessments for OPG formation, optimized screening for early visual impairment, and vision restoration therapies.
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